Catherine Ronet and Mary-Anne Hartley of the University of Lausanne in Switzerland will target a naturally occurring RNA virus in Leishmania parasites (LRV) that not only aids parasite survival, but also causes a destructive inflammatory response in humans. They will develop and refine a LRV diagnostic device and formulate the virus as a vaccine candidate for the prevention and treatment of the leishmaniasis.
Grant ID
OPP1056785
Show on Hub
On
Show on Spoke
On
Follow-on Funding
Off
Lead Funding Organization
Initiatives
Principal Investigator
Award Manager
Individual Funder Information
Funding Organization
Funding Amount (in original currency)
100000.00
Funding Currency
USD
Funding Amount (in USD)
100000.00
Project Type
Project Primary Sector
Funding Date Range
-
Funding Total (In US dollars)
100000.00
Co-Funded
False